Is bariatric surgery worth its costs?

Obesity Surgery

Volumn 9, Issue 5, 1999, Pages 480-483

  Hauri, P ^a   Horber, F F ^b   Sendi, P ^a,c  

^a Med Info Technol Assess Res G   (Switzerland)

^b KLINIK HIRSLANDEN   (Switzerland)

^c MITARG GmbH   (Switzerland)

Author keywords

Cost benefit analysis; Morbid obesity; Surgery

Indexed keywords

ARTICLE; BARIATRIC SURGERY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HUMAN; MEDICAL LITERATURE; MORBID OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE;

COST-BENEFIT ANALYSIS; FEMALE; GASTROPLASTY; HEALTH CARE COSTS; HUMANS; MALE; OBESITY, MORBID; SWITZERLAND;

EID: 0032747839     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1381/096089299765552783     Document Type: Article

References (25)

1. 1. Wolf AM, Colditz GA. The cost of obesity. The US perspective. PharmacoEconomics 1994; 5 (suppl. 1): 34-7.
2. 2. Birmingham CL, Muller JL, Palepu A, et al. The cost of obesity in Canada. Can Med Assoc J 1999; 160: 483-8.
3. 3. Segal L, Carter R, Zimet P. The cost of obesity. The Australian perspective. PharmacoEconomics 1994; 5 (suppl. 1): 45-52.
4. 4. Seidell JC, Deerenberg I. Obesity in Europe. Prevalence and consequences for use of medical care. PharmacoEconomics 1994; 5 (suppl. 1); 38-44.
5. 5. Bender R, Trautner C, Spraul M, et al. Assessment of excess mortality in obesity. Am J Epidemiol 1998; 147: 42-8.
6. 6. Martin LF, Tan TL, Horn JR, et al. Comparison of the costs associated with medical and surgical treatment of obesity. Surgery 1995; 118: 599-606.
7. 7. Scopinaro N. The IFSO and obesity surgery throughout the world. International Federation for the Surgery of Obesity. Obes Surg 1998; 8: 3-8.
8. 8. Srinivasan P. Retrieval feedback in MEDLINE. J Am Med Inform Assoc 1996; 3: 157-67.
9. 9. Drummond M, O'Brien B, Stoddard G, et al. Methods for Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997.
10. 10. Petitti DB. Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis; Methods for Quantitative Synthesis in Medicine. Oxford: Oxford University Press 1994.
11. 11. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276; 1339-41.
12. 12. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-8.
13. 13. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1172-7.
14. 14. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81.
15. 15. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J 1993; 148: 913-7.
16. 16. Drummond MF, Richardson WS, O'Brien BJ, et al. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1997; 277: 1552-7.
17. 17. O'Brien BJ, Heyland D, Richardson WS, et al. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group users' guides to the medical literature. JAMA 1997; 277: 1802-6.
18. 18. Fryback DG, Lawrence WF, Jr. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making 1997; 17: 276-84.
19. 19. Gafni A. Alternatives to the QALY measure for economic evaluations. Support Care Cancer 1997; 5: 105-11.
20. 20. Ried W. QALYs versus HYEs - what's right and what's wrong. A review of the controversy. J Health Econ 1998; 17: 6007-25.
21. 21. Gafni A, Birch S, Mehrez A. Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted life-year). J. Health Econ 1993; 12: 325-39.
22. 22. Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ 1998; 7: 1-7.
23. 23. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ 1997; 6: 511-4.
24. 24. O'Brien B, Gafni A. When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making 1996; 16: 288-99.
25. 25. Zarnke KB, Levine MA, O'Brien BJ. Cost-benefit analyses in the health-care literature: don't judge a study by its label. J. Clin Epidemiol 1997; 50: 813-22.